STAGE IV LUNG CANCER AJCC V8

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This early-phase study tests a combination of two drugs, osimertinib and tegavivint, as the first treatment for people with a certain type of advanced lung cancer that has spread. The goal is to find the safest dose and see if the combination helps shrink tumors. About 24 adults …

This study tests a radiation method that treats the entire brain and spinal cord but avoids the hippocampus, a memory center. It is for adults with breast or lung cancer that has spread to the fluid and tissues around the brain and spine. The goal is to see if this approach can d…

This study tests whether adding an experimental drug (SX-682) to a standard immunotherapy (pembrolizumab) helps shrink or control advanced non-small cell lung cancer. About 30 adults with stage IIIC or IV lung cancer that hasn't been treated yet will receive both drugs. The goal …

This study compares two types of radiation for people with small cell lung cancer that has spread to the brain. One method uses a precise, high-dose beam to each tumor, while the other treats the whole brain but avoids the memory center. The goal is to see which approach better p…

This early-stage trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—in adults with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune sy…

This study tests if a precise type of proton radiation (pCSI) can help people with breast or lung cancer that has spread to the fluid-filled space around the brain and spinal cord live longer than standard x-ray radiation. About 115 participants will be randomly assigned to one o…

This study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…

This early-phase study tests a combination of two ways to give the immunotherapy drug nivolumab: through a vein and directly into the fluid around the spine. It is for people with melanoma or lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal di…

This study tests a type of radiation therapy called craniospinal irradiation for people whose breast or lung cancer has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this treatment can help control the cancer in these areas. About 35 adult…

This study tests a combination of chemotherapy (temozolomide) and immunotherapy (atezolizumab) for people with small cell lung cancer that has spread or returned after initial treatment. The goal is to see if this combo can shrink tumors and help patients live longer. About 56 ad…

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen while on immunotherapy alone. About 20 adults with stage III or IV lung cancer w…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV non-squamous non-small cell lung cancer will be randomly assigned to re…

This study tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see how well the combination works. About 69 participants will take part in this early-p…

This early-phase trial tests a new drug (PBF-1129) combined with an existing immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Researchers also want to…

This study tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe and can shrink tumors. About 37 adults who have already trie…

This early-stage trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 15 adults who have already tried a KRAS-targeting drug will re…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) works better than immunotherapy alone for adults aged 70 and older with advanced non-small cell lung cancer. The goal is to see which approach helps patients live longer and keeps the cancer from growin…

This study tests whether adding ramucirumab to tepotinib helps control advanced non-small cell lung cancer with a specific MET gene change. About 56 people with stage IV or recurrent cancer will receive either tepotinib alone or with ramucirumab. The goal is to see if the combina…

This early-phase study tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose tumors stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Resea…

This early study tests whether adding low-dose IL-2 to the immunotherapy drug pembrolizumab can better activate the immune system against stage IV non-small cell lung cancer. About 15 people with untreated advanced lung cancer will receive the combination. The goal is to see if t…

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 people with advanced LKB1-mutant lung adenocarcinoma that has stopped responding to standard anti-PD1 treatment. The goal is to see if this triple therapy ca…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study tests whether adding the drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can keep extensive-stage small cell lung cancer from growing longer than immunotherapy alone. About 45 adults whose cancer responded to initial chemo-immunotherapy will par…

This study tests a new drug combination (GT103 plus pembrolizumab) in people with advanced or spreading non-small cell lung cancer that has a specific gene change called STK11. The goal is to see if the combo can shrink tumors or slow the cancer better than current options. About…

This study tests a special type of radiation called grid therapy combined with standard immunotherapy for people with stage IV non-small cell lung cancer that has gotten worse despite treatment. Grid therapy delivers high doses of radiation to small parts of the tumor, which may …

This study tests a special dye that attaches to lung cancer cells and makes them glow under a special camera during surgery. The goal is to help surgeons see and remove all cancer tissue more accurately. About 30 adults with lung cancer or lung metastases will receive the dye bef…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study tests a method called adaptive radiation planning for people with stage II to IV non-small cell lung cancer. Normally, radiation plans stay the same throughout treatment, but tumors can shrink, causing radiation to hit healthy tissue. By updating the plan at set times,…

This study tests whether giving radiation in three smaller doses (fractionated SRS) is better than a single large dose (standard SRS) for treating cancer that has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be enrolled. The goa…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve cancer symptoms without causing too many side effects. …

This study tests whether a yoga program designed for both patients and their family caregivers can improve physical function, fatigue, sleep, and quality of life. It includes 400 people with lung or esophageal cancer who are getting radiation therapy, plus their caregivers. Parti…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 therapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to und…

This study tests whether a short screening tool can help people with advanced lung cancer better understand their illness and treatment options. Researchers will compare patients who use the tool with those who receive usual care. The goal is to see if the tool helps patients mak…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung, or genitour…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 adults who haven't had prior …

This study looks at 800 people with advanced lung, pancreatic, or colorectal cancer to find different types of cancer-related weight and muscle loss (cachexia). Researchers will track symptoms, physical function, and blood markers over time. The goal is to identify distinct subty…

This study looks at how often people with metastatic non-small cell lung cancer have trouble sleeping. Researchers will ask 60 participants to fill out a sleep questionnaire to measure insomnia severity. The goal is to better understand sleep problems in this group, not to test a…

This study looks at how biomarkers (like DNA from tumors in the blood) can help doctors predict which patients with advanced non-small cell lung cancer will respond to immunotherapy. It involves 535 participants and aims to use these markers to personalize treatment, especially w…

This study tests whether a portable device that creates electric fields is safe and practical for treating cancer that has spread to the lining of the spine. It includes up to 5 adults with breast or lung cancer that has spread to the spinal fluid and spine. The goal is to see if…

This study is testing whether a special communication tool helps doctors and lung cancer patients make treatment decisions together more effectively. The tool guides conversations about treatment options, benefits, and risks while considering each patient's personal situation and…